The purpose of this study is to determine how many chronic users of antisecretory medication can stop after a test for a bacteria associated with peptic ulcer disease. This is evaluated in a discontinuation trial.
Background: Testing patients with a Helicobacter pylori (Hp) 13C-urea breath test and treatment with eradication of Hp if positive - test-and-eradicate - have proven as effective and safe as prompt endoscopy for management of dyspeptic patients in a primary health care setting. However, empirical treatment with an ulcer-healing drug is often used in dyspeptic patients, as reflected in a growing proportion of long-term users without known ulcer or gastro-oesophageal reflux disease (GORD). This group of patients contributed to 59% of the total use of acid-suppressive medication in the County of Funen in Denmark in 1997. Aim/purpose: It is our aim to examine the need for continued medication with prescribed, acid-suppressive drugs in primary health care. Our secondary objective is to investigate the profile of symptoms, quality of life, Hp-status, consumption of drugs and use of health care services in the same context. Methods: To conduct a randomised, placebo-controlled, blinded, clinical discontinuation trial, 500 long-term users of acid-suppressive drugs are identified by general practitioners. Long-term use is defined as treatment for more than 2x28 days during a 6-month period. The patients are included with a 13C-urea Hp-breath test and randomised for treatment with PPI or placebo. Hp-positive patients are treated with an Hp-eradication treatment. The patients are followed for 1 year; the primary outcome is the need for open treatment with acid-suppressive medication due to failing symptom relief despite treatment with the randomised project medication. The patients are to fill in a symptom and medication diary every month for periods of 1 week. Questionnaires are to be given to the patients 3 times during the follow-up period. Medication diaries as well as questionnaires have proven useful in similar studies. The main outcome is analysed using Kaplan-Meier survival estimates analysis.
Study Type
INTERVENTIONAL
Allocation
RANDOMIZED
Purpose
TREATMENT
Masking
QUADRUPLE
Enrollment
171
esomeprazole, original Nexium, 40 mg pills Up to once a day
Breath test done at entry to find Helicobacter pylori
Department of Medical Gastroenterology, Odense University Hospital
Odense, Denmark
Failure of patient perceived symptom control despite treatment with project medication
Time frame: 12 months
Gastrointestinal symptoms
Time frame: 12 months
Quality of life
Time frame: 12 months
GPs and patients satisfaction
Time frame: 12 months
Helicobacter pylori status
Time frame: At enrolement
Resource consumption
Time frame: 12 months
Days without symptoms
Time frame: 12 months
Use of otc-medication
Time frame: 12 months
Sick-leave days
Time frame: 12 months
Number of visits to primary and secondary healthcare system
Time frame: 12 months
This platform is for informational purposes only and does not constitute medical advice. Always consult a qualified healthcare professional.